The cell line with two rounds of lentiviral transduction (higher expression of FBP1, Supplementary Figure S1) demonstrated a significantly higher percentage (CD14+: 27.05%) of viable CD14+ blasts (a biomarker of monocytic differentiation [17]) when compared to both the naïve control (CD14+: 1.287%) and the cell line (CD14+: 5.14%) with only one round of FBP1 lentiviral transduction, indicating that increased FBP1 overexpression could lead to enhanced differentiation of leukemia cells (Figure 2B). This evidence concerns the gene CD14 and leukemia.